Home › Companies › MIST

Milestone Pharmaceuticals Inc.

MIST Lead: Phase 3 6 Biotech Distilled articles ↓

Cardiovascular Small Molecule

Most recent annual filing: 2026-03-15

Pipeline (3 active programs)

CARDAMYST

TACHYMIST · etripamil

Small Molecule Target: L-type calcium channel, AV node, calcium channel

Paroxysmal Supraventricular Tachycardia Phase 2 nasal Everest Medicines

etripamil

Small Molecule Target: L-type calcium channel, AV node

Atrial Fibrillation with Rapid Ventricular Rate Phase 3 nasal

CARDAMYST

etripamil

Small Molecule Target: calcium channel

Atrial Fibrillation nasal

Biotech Distilled coverage (6)

2026-05-14 UPDATE: Milestone Pharmaceuticals (MIST) - The First Scoreboard, and a Fresh $100M ATM 🔒 Paid
2026-04-27 UPDATE: Milestone Pharmaceuticals (MIST) - Express Scripts Says Yes, and the Stock Wakes Up 🔒 Paid
2026-03-21 UPDATE: Milestone Pharmaceuticals (MIST) - $200M War Chest and Slaying the Hypotension Bear 🔒 Paid
2026-02-14 Update: Milestone Pharmaceuticals (MIST) - Building the Foundation for Launch (and Deals) 🔒 Paid
2026-01-30 UPDATE: Milestone Pharmaceuticals (MIST) - CARDAMYST is on the Shelf. The Clock Starts Now.
2025-12-15 Milestone Pharmaceuticals (MIST): Scientific Due Diligence for CARDAMYST (etripamil) and Pipeline

Articles open on Substack. Some deep dives are subscriber-only.